Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Leveraging Biomarkers in Endometrial Cancer Requires Careful Integration, More Research

January 27th 2022

Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.

Dr. Corr on the Utilization of Molecular Profiling in Endometrial Cancer

January 26th 2022

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.

FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations

January 25th 2022

The FDA has granted a fast track designation to CX-5461 (Pidnarulex) as a potential therapeutic option for patients with breast and ovarian cancers that harbor BRCA1/2, PALB2, or other homologous recombination deficiency mutations.

Pembrolizumab Elicits Robust, Durable Antitumor Activity in MSI-H Advanced Endometrial Cancer

January 17th 2022

Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.

Pembrolizumab/Lenvatinib Approved in Japan for Endometrial Cancer Following Progression on Chemo

January 3rd 2022

The Japanese Ministry of Health, Labour, and Welfare has approved the combination of pembrolizumab plus lenvatinib for use in patients with unresectable, advanced, or recurrent endometrial carcinoma that has progressed on chemotherapy.

Practice-Changing Data From 2021 Sets Tone for New Year

December 29th 2021

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.

Cervical Cancer Management: Looking Toward the Future of Care

December 8th 2021

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.

Metastatic Cervical Cancer: Practical Considerations for Tisotumab Vedotin Use

December 8th 2021

Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.

Image-Guided Intensity-Modulated Radiotherapy Shows Reduced Toxicity in Cervical Cancer

December 4th 2021

Image-guided intensity-modulated radiotherapy caused less toxicity compared with three-dimensional conformal radiation therapy with no difference in disease outcomes in patients with cervical cancer undergoing postoperative radiation therapy.

Dr. Pothuri on the Challenges of POLE Testing in Endometrial Cancer

December 2nd 2021

Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer.

Metastatic Cervical Cancer: ADC Adverse Event Management

December 2nd 2021

Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.

Tisotumab Vedotin: A Second-Line ADC Approval in Metastatic Cervical Cancer

December 2nd 2021

Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.

Retifanlimab Shows Promising Antitumor Activity in Advanced Endometrial Cancer

December 1st 2021

Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.

Practical Advice on Sequencing Therapies and the Care of Cervical Cancer Patients

November 30th 2021

Closing out his discussion on the treatment of cervical cancer, Robert L. Coleman, MD, FACOG, FACS, provides thoughts on the optimal sequencing of therapy and importance of clinical trials.

Advanced Cervical Cancer: Toxicity Management With Balstilimab + Zalifrelimab

November 30th 2021

Robert L. Coleman, MD, FACOG, FACS, shares practical advice on managing toxicities while treating cervical cancer with the combination of balstilimab and zalifrelimab.

Combining Balstilimab With Zalifrelimab in Patients With Advanced Cervical Cancer

November 30th 2021

Expert insight on the combination of balstilimab, a PD-1 inhibitor, and zalifrelimab, a CTLA-4 inhibitor, in patients with recurrent or metastatic cervical cancer.

Balstilimab in Advanced Cervical Cancer: Rationale and Key Efficacy Outcomes

November 30th 2021

Focusing on novel immune checkpoint inhibitors, Robert L. Coleman, MD, FACOG, FACS, breaks down preclinical and clinical data that support use of balstilimab in patients with advanced cervical cancer.

An Overview of the Cervical Cancer Landscape: Key Advances and Recent Approvals

November 30th 2021

Robert L. Coleman, MD, FACOG, FACS, reviews the treatment landscape of cervical cancer and identifies recent approvals that have improved patient care.

European Commission Approves Pembrolizumab/Lenvatinib for Advanced or Recurrent Endometrial Cancer

November 29th 2021

The European Commission has granted an approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.